Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leigh Casper

Nurse Practitioner, Acute Care Salisbury, NC Nurse Practitioner

NPI 1467000604 CMS profile 7216917

1809 Brenner Ave Ste 102, Salisbury, NC 28144

Open in the dashboard

General payments

$11,963

647 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leigh Casper of Salisbury, NC is reported in the CMS Open Payments database as having received $11,963 across 647 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,160 111
2024 General $2,432 138
2023 General $2,676 145
2022 General $2,678 149
2021 General $2,016 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leigh Casper
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Leigh Casper were reported at $2,160. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Leigh Casper Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,016 $123 $38–$327 $132
2022 $2,678 $130 $44–$369 $149
2023 $2,676 $144 $49–$410 $160
2024 $2,432 $146 $48–$433 $164
2025 $2,160 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,603 160 payments
  2. Gilead Sciences, Inc. $1,119 69 payments
  3. Janssen Biotech, Inc. $1,058 45 payments
  4. Ardelyx, Inc. $880 60 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $784 47 payments
  6. Celgene Corporation $766 52 payments
  7. Pfizer Inc. $577 32 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $548 23 payments
  9. Ironwood Pharmaceuticals, Inc $529 28 payments
  10. Genzyme Corporation $314 15 payments
  11. Other $2,785 116 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,736 644 payments
  2. Education $227 3 payments
Products named General payments · program years 2021–2025
  1. ZEPOSIA $1,003 53 payments
  2. RINVOQ $930 56 payments
  3. IBSRELA $880 60 payments
  4. STELARA $844 36 payments
  5. MAVYRET $779 46 payments
  6. XIFAXAN $574 32 payments
  7. Linzess Gi $529 28 payments
  8. LINZESS Gastroenterology $464 30 payments
  9. XELJANZ $452 26 payments
  10. SIMPONI ARIA $449 25 payments
  11. Other $7,062 371 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

647 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record